Skip to main content
. 2010 Jan 8;95(2):829–836. doi: 10.1210/jc.2009-1487

Figure 1.

Figure 1

Plasma hsCRP and IL-6 in patients with the MetS before and after 12 wk of treatment with fenofibrate or placebo. Fenofibrate significantly reduced plasma hsCRP (−49.5%; P = 0.005) and IL-6 (−31.8%; P = 0.03) compared to placebo after 12 wk of treatment in patients with the MetS.